Supplementary materials: Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis

These are peer-reviewed supplementary materials for the article 'Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: Meta-analysis of patient preferences for home versus hospital treatment.Supplementary Figure 2: LQI 4-scale scores.Supplementary Figure 3: SF-36 PCS and MCS results.Supplementary Table 1: PubMed search termsSupplementary Table 2: PICOS table summarizing inclusion/exclusion criteriaSupplementary Table 3: Treatment satisfaction results, TSQM and rating scalesAim: Several studies have found subcutaneous (SC) and intravenous (IV) administration of similar drugs for long-lasting immunological and autoimmune diseases to have similar clinical effectiveness, meaning that what patients report they prefer is, or should be, a major factor in treatment choices. Therefore, it is important to systematically compile evidence regarding patient preferences, treatment satisfaction and health-related quality of life (HRQL) using SC or IV administration of the same drug. Materials & methods: PubMed database searches were run on 15 October 2021. Studies involving patients with experience of both home-based SC and hospital-based IV administration of immunoglobulins or biological therapies for the treatment of any autoimmune disease or primary immunodeficiencies (PIDs) were included. The outcomes assessed were patient preferences, treatment satisfaction and HRQL. Preference data were meta-analyzed using a random-effects model. Results: In total, 3504 citations were screened, and 46 publications describing 37 studies were included in the review. There was a strong overall preference for SC over IV administration, with similar results seen for PIDs and autoimmune diseases: PID, 80% (95% confidence interval [CI], 64–94%) preferred SC; autoimmune diseases, 83% (95% CI: 73–92%); overall, 82% (95% CI: 75–89%). The meta-analysis also found that 84% (95% CI: 75–92%) of patients preferred administration at home to treatment in hospital. Analysis of treatment satisfaction using the life quality index found consistently better treatment interference and treatment setting scores with SC administration than with IV administration. Conclusion: Compared with IV infusions in hospital, patients tend to prefer, to be more satisfied with and to report better HRQL with SC administration of the same drug at home, primarily due to the greater convenience. This study contributes to evidence-based care of patients with autoimmune diseases or PIDs.

本为《免疫失调成人皮下或静脉注射药物治疗的报告偏好：一项系统综述与荟萃分析》一文的同行评审补充材料。补充图1：居家治疗与医院治疗的偏好荟萃分析。补充图2：LQI 4级评分。补充图3：SF-36生理成分评分和 Mental Component评分结果。补充表1：PubMed检索词。补充表2：PICOS表总结纳入/排除标准。补充表3：治疗满意度结果，TSQM和评分量表。研究目标：多项研究发现，对于长期免疫和自身免疫性疾病，皮下（SC）和静脉（IV）注射相同药物的疗效相似，这意味着患者报告的偏好应成为治疗选择中的主要因素。因此，系统地整理有关患者偏好、治疗满意度和与健康相关的生活质量（HRQL）方面的证据至关重要，特别是使用SC或IV同种药物进行注射。材料与方法：于2021年10月15日在PubMed数据库中进行了检索。纳入涉及在家进行SC注射和在医院进行IV注射免疫球蛋白或生物治疗，以治疗任何自身免疫疾病或原发性免疫缺陷症（PIDs）的患者研究。评估的结局包括患者偏好、治疗满意度和HRQL。偏好数据采用随机效应模型进行荟萃分析。结果：共筛选3504篇文献，纳入综述的46篇出版物描述了37项研究。总体上，对SC注射的偏好强于IV注射，PID和自身免疫疾病的结论相似：PID，80%（95%置信区间[CI]，64–94%）偏好SC；自身免疫疾病，83%（95% CI：73–92%）；总体，82%（95% CI：75–89%）。荟萃分析还发现，84%（95% CI：75–92%）的患者偏好在家治疗而非医院治疗。使用生活质量指数分析治疗满意度时，发现与IV注射相比，SC注射在治疗干扰和治疗环境评分上具有持续更好的效果。结论：与医院静脉注射相比，患者更倾向于在家进行相同药物的SC注射，满意度更高，并报告更好的HRQL，这主要归因于其更大的便利性。本研究为自身免疫疾病或PIDs患者的循证护理做出了贡献。